All In Biotech

Drug Trial Radar · NCT05832229

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

Liver Cirrhosis Network (LCN) Rosuvastatin Efficacy and Safety for Cirrhosis in the United States (RESCU): A Double-Blind Randomized, Placebo-Controlled Phase 2 Study

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

260

Planned (sponsor's estimate)

Start

Dec 7, 2023

Primary completion

Aug 31, 2029

Study completion Aug 31, 2029

Sponsor

Sponsor type
NIH
Collaborators
The Cleveland Clinic; Columbia University; Weill Medical College of Cornell University; Duke University; Mayo Clinic; University of Miami; University of Michigan; University of California, San Diego; University of California, San Francisco; LAC+USC Medical Center; Virginia Commonwealth University; National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer Institute (NCI); University of Southern California
First posted
Apr 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.

Conditions

  • Cirrhosis
  • Cirrhosis, Liver
  • Cirrhosis Early
  • Cirrhosis Due to Hepatitis B
  • Cirrhosis Advanced
  • Cirrhosis Infectious
  • Cirrhosis Alcoholic
  • Cirrhosis Due to Hepatitis C

Interventions

  • RosuvastatinDrug

    Patients meeting all eligibility criteria will be assigned to a randomization arm prior to initiation of a 4-week lead-in phase of the study. All participants will undergo a 4-week, open-label active run-in phase to evaluate initial safety and adherence to rosuvastatin. During this active run-phase, all participants will receive target dose rosuvastatin-- 20 mg daily . After the active run-in phase, all participants will continue with their pre-assigned randomization (1:1) treatment of rosuvastatin 20 mg daily or matching placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change in liver stiffnessTime frame: 96 weeks

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • University of California San Diego NAFLD Research Center

    La Jolla, California · Recruiting

  • Keck Medical Center of USC

    Los Angeles, California · Recruiting

  • LAC + USC Medical Center

    Los Angeles, California · Recruiting

  • UCSF/Zuckerberg San Francisco General Hospital and Trauma Center

    San Francisco, California · Recruiting

  • UCSF Medical Center

    San Francisco, California · Recruiting

  • University of Miami Health System

    Miami, Florida · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • New York Presbyterian/Weill Cornell

    New York, New York · Recruiting

  • Columbia University Iriving School of Medicine

    New York, New York · Recruiting

  • Duke Liver Center

    Durham, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Virginia Commonwealth University

    Richmond, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.